Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate the impact of once-weekly exenatide (EQW) on microvascular and cardiovascular (CV) outcomes by baseline renal function in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). RESEARCH DESIGN AND METHODS: Least squares mean difference (LSMD) in estimated glomerular filtration rate (eGFR) from baseline between the EQW and placebo groups was calculated for 13,844 participants. Cox regression models were used to estimate effects by group on incident macroalbuminuria, retinopathy, and major adverse CV events (MACE). Interval-censored time-to-event models estimated effects on renal composite 1 (40% eGFR decline, renal replacement, or renal death) and renal composite 2 (composite 1 variables plus macroalbuminuria). RESULTS: EQW did not change eGFR significantly (LSMD 0.21 mL/min/1.73 m2 [95% CI −0.27 to 0.70]). Macroalbuminuria occurred in 2.2% of patients in the EQW group and in 2.5% of those in the placebo group (hazard ratio [HR] 0.87 [95% CI 0.70–1.07]). Neither renal composite was reduced with EQW in unadjusted analyses, but renal composite 2 was reduced after adjustment (HR 0.85 [95% CI 0.74–0.98]). Retinopathy rates did not differ by treatment group or in the HbA1c-lowering or prior retinopathy subgroups. CV outcomes in those with eGFR <60 mL/min/1.73 m2 did not differ by group. Those with eGFR ≥60 mL/min/1.73 m2 had nominal risk reductions for MACE, all-cause mortality, and CV death, but interactions by renal function group were significant for only stroke (HR 0.74 [95% CI 0.58–0.93]; P for interaction = 0.035) and CV death (HR 1.08 [95% CI 0.85–1.38]; P for interaction = 0.031). CONCLUSIONS: EQW had no impact on unadjusted retinopathy or renal outcomes. CV risk was modestly reduced only in those with eGFR ≥60 mL/min/1.73 m2 in analyses unadjusted for multiplicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“subsequent analysis of the data adjusted for baseline demographics and comorbidities revealed a significant improvement in the renal composite outcome, mainly mediated by a lower incidence of macroalbuminuria [58].”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Self-citationCanagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citation
Cited by
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Self-citationKDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Self-citationde Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022) · Diabetes Care · doi:10.2337/dci22-0027 · Cited by 919
Self-citationde Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022) · Kidney International · doi:10.1016/j.kint.2022.08.012 · Cited by 353
Self-citationRossing, P., Baeres, F. M. M., Bakris, G., Bosch-Traberg, H., Gislum, M., Gough, S. C. L., Idorn, T., Lawson, J., Mahaffey, K. W., Mann, J. F. E., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad009 · Cited by 242
“73 m2 for ≥30 days in AMPLITUDE-O [6, 7, 10, 13, 38, 43].”
Self-citationIncretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00367-2 · Cited by 193
Bethel, M. A., Diaz, R., Castellana, N., Bhattacharya, I., Gerstein, H. C., & Lakshmanan, M. C. (2021) · Diabetes Care · doi:10.2337/dc20-1815 · Cited by 151
Self-citationDiabetic retinopathy: Screening, prevention, and treatment
Chong, D. D., Das, N., & Singh, R. P. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.24028 · Cited by 170
GLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms
Kawanami, D., & Takashi, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00967 · Cited by 129
Advances in the management of chronic kidney disease
Chen, T. K., Hoenig, M. P., Nitsch, D., & Grams, M. E. (2023) · BMJ · doi:10.1136/bmj-2022-074216 · Cited by 122
Zhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01676-5 · Cited by 96
“Out of 17 studies, 3 studies were compared nerenone [16,17,28-30] with placebo; 8 studies were compared SGLT2i (Empaglifozin [31-35], Canaglifozin [7,36-42], Dapaglifozin [43-47], Ertuglifozin [48-50], and Sotaglifozin [51,52]) with placebo; 6 studies compared GLP-1 RA (Dulaglutide [53,54], Albiglutide [55], Exenatide…”
BackgroundInfluentialGLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
Yu, J. H., Park, S. Y., Lee, D. Y., Kim, N. H., & Seo, J. A. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.22.001 · Cited by 103
Kanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650.pub2 · Cited by 111
Chen, J., Hsu, T., Liu, J.-H., Pan, H., Lai, C., Yang, S., & Wu, V. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.11.013 · Cited by 81
Granata, A., Maccarrone, R., Anzaldi, M., Leonardi, G., Pesce, F., Amico, F., Gesualdo, L., & Corrao, S. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac069 · Cited by 54
“Although exenatide did not produce any significant improvement in eGFR decline and incidence of ESRD and renal-related death in the EXSCEL trial, subsequent analysis of the data adjusted for baseline demographics and comorbidities revealed a significant improvement in the renal composite outcome,mainlymediated by a lo…”
Stephens, J. W., Brown, K. E., & Min, T. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13942 · Cited by 61
“Renal Outcomes were also evaluated in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) where a 40% decrease in a composite end point of eGFR decline, renal replacement, renal death or new macroalbuminuria was siobserved.(103)”
MethodMima, A., Nomura, A., & Fujii, T. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115032 · Cited by 49
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
Yin, W. L., Bain, S. C., & Min, T. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00798-x · Cited by 45
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 48
Mima, A., Gotoda, H., Lee, R., Murakami, A., Akai, R., & Lee, S. (2023) · Metabolism Open · doi:10.1016/j.metop.2023.100236 · Cited by 48
SKOLNIK, N., & Style, A. J. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01050-w · Cited by 45
von Scholten, B. J., Kreiner, F. F., Rasmussen, S., Rossing, P. R., & Idorn, T. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221112490 · Cited by 46
Obesity-Related Kidney Disease: Current Understanding and Future Perspectives
Kreiner, F. F., Schytz, P. A., Heerspink, H. J. L., von Scholten, B. J., & Idorn, T. (2023) · Biomedicines · doi:10.3390/biomedicines11092498 · Cited by 52
van der Aart‐van der Beek, A. B., Clegg, L. E., Penland, R. C., Boulton, D. W., Sjöström, C. D., Mentz, R. J., Holman, R. R., & Heerspink, H. J. L. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14175 · Cited by 37
“73 m.(2,6) In addition, in the AWARD-7 trial, the effect of dulaglutide on clinical kidney outcomes”
BackgroundSelf-citationEffects of newer-generation anti-diabetics on diabetic retinopathy: a critical review
Ntentakis, D. P., Correa, V., Ntentaki, A. M., Delavogia, E., Narimatsu, T., Efstathiou, N. E., & Vavvas, D. G. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06236-5 · Cited by 43
“Post hoc analysis of AE reports from the EXSCEL trial found no differences in DR incidence or severity between patients receiving exenatide once weekly versus placebo in addition to standard of care, over a median period of 3.2 years [72].”
InfluentialRenoprotective mechanisms of glucagon-like peptide-1 receptor agonists
Chen, J., Cooper, M., & Coughlan, M. T. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101641 · Cited by 35
van der Aart ‐ van der Beek, A. B., van Raalte, D. H., Guja, C., Hoogenberg, K., Suchower, L. J., Hardy, E., Sjöström, C. D., & Heerspink, H. J. L. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14067 · Cited by 28
“A renal composite endpoint of sustained 40% eGFR drop, end-stage renal disease, and new macroalbuminuria was improved in the EXSCEL trial by exenatide compared to placebo, although the effect was only statistically significant after multivariable adjustment.(18) Other GLP-1RA trials have also suggested beneficial kidn…”
BackgroundLi, X., Song, Y., Guo, T., Xiao, G., & Li, Q. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101366 · Cited by 33
Kelly, M., Lewis, J., Rao, H., Carter, J., Portillo, I., & Beuttler, R. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2737 · Cited by 29
Feng, Y., Zhu, J., Wang, Q., Cao, H., He, F., Guan, Y., Li, D., Yan, J., Yang, J., Xia, Y., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.999715 · Cited by 31
Vanek, L., Kurnikowski, A., Krenn, S., Mussnig, S., & Hecking, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15967 · Cited by 28
Cao, H., Liu, T., Wang, L., & Ji, Q. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14702 · Cited by 33
Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease
Wang, X., Zhang, H., Zhang, Q., Guan, M., Sheng, S., Mo, W., Zou, M., Li, J., Bi, J., Tang, X., et al. (2020) · American Journal of Nephrology · doi:10.1159/000510255 · Cited by 29
Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
MacIsaac, R. J., Trevella, P., & Ekinci, E. I. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13609 · Cited by 31
“28 Despite this, a kidney function composite end point of ≥ 30% eGFR decline or ESKD has been reported to be significantly decreased with exenatide treatment compared with placebo (HR: 0.87, 95% CI: 0.77 – 0.99, p = 0.03) in the EXSCEL trial.”
InfluentialMechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists
Tommerdahl, K. L., Nadeau, K. J., & Bjornstad, P. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.06.001 · Cited by 29
Bulum, T. (2022) · Biomedicines · doi:10.3390/biomedicines10102586 · Cited by 31
“In the EXSCEL trial, exendin-4 analog exenatide, compared to placebo, decreased the risk of the onset of macroalbuminuria, dialysis or transplantation, renal death, and risk of GFR decline by 40% [96].”
BackgroundNovel therapeutic agents for the treatment of diabetic kidney disease
Hartman, R. E., Rao, S., Churchwell, M. D., & Lewis, S. J. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1811231 · Cited by 27
Natale, P., Green, S. C., Tunnicliffe, D. J., Pellegrino, G., Toyama, T., & Strippoli, G. F. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015849.pub2 · Cited by 40
Górriz, J. L., Romera, I., Cobo, A., O’Brien, P. D., & Merino-Torres, J. F. (2022) · Diabetes Therapy · doi:10.1007/s13300-021-01198-5 · Cited by 31
Aguilar-Ballester, M., Hurtado-Genovés, G., Taberner-Cortés, A., Herrero-Cervera, A., Martínez‐Hervás, S., & Navarro, H. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020660 · Cited by 29
Potential kidney protective effects of glucagon‐like peptide‐1 receptor agonists
Trevella, P., Ekinci, E. I., & MacIsaac, R. J. (2024) · Nephrology · doi:10.1111/nep.14336 · Cited by 26
Quagliariello, V., Canale, M. L., Bisceglia, I., Iovine, M., Giordano, V., Giacobbe, I., Scherillo, M., Gabrielli, D., Maurea, C., Barbato, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011299 · Cited by 23
“The safety profile, including the incidence of gastrointestinal events and hypoglycemia, was comparable to placebo [82] (Table 1).”
Xie, Z., Yang, Z., Tian, D., & Chen, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1618079 · Cited by 22
Rossing, P. R., Bain, S. C., Bosch‐Traberg, H., Sokareva, E., Heerspink, H. J. L., Rasmussen, S., & Mellbin, L. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01949-7 · Cited by 24
“However, several CVOTs have included participants with reduced kidney function [2–5, 14] , enabling the Previous post hoc analyses of the SUSTAIN and PIO-NEER programmes have evaluated the effect of sema-glutide in people with T2D and established CVD and/ or CKD, or CV risk factors [17–20], and how…”
BackgroundGLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01036-y · Cited by 22
Hasebe, M., Su, C., Keidai, Y., Minamino, H., Yabe, D., Inagaki, N., & Yoshiji, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70121 · Cited by 16
Glucagon-like Peptide-1 Receptor Agonists
Jeon, J. Y., & Kim, H. J. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_14 · Cited by 16
Ruan, Z., Yang, L., Shi, H., Yue, X., Wang, Y., Liang, M., & Hu, H. (2021) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1860022 · Cited by 15
“However, exenatide ER and lixisenatide did not display benefits compared with placebo in the clinical trials of EXSCEL [56] and ELIXA [57], respectively.”
Novel GLP-1 analog supaglutide improves glucose homeostasis in diabetic monkeys
Cui, Q., Liao, Y., Jiang, Y., Huang, X., Tao, W., Zhou, Q., Shao, A., Zhao, Y., Li, J., Ma, A., et al. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0255 · Cited by 16
Idzerda, N. M. A., Clegg, L. E., Hernandez, A. F., Bakris, G. L., Penland, R. C., Boulton, D. W., Bethel, M. A., Holman, R. R., & Heerspink, H. J. L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13958 · Cited by 16
Self-citationStandl, E., & Schnell, O. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108054 · Cited by 14
Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease
Alicic, R. Z., & Neumiller, J. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010201 · Cited by 16
Finerenone in diabetic kidney disease: a new frontier for slowing disease progression
Alhomoud, I. S., Albekery, M. A., Alqadi, R., Alqumia, A., Khan, R. A., Sahlawi, M. A. A., & Mulhim, M. Y. A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1580645 · Cited by 17
Siniukovich, A., Travlos, C. K., Freedman, S., Mavrakanas, T. A., & Gariani, K. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01831-4 · Cited by 14
“However, no interaction was observed between CKD status and the effect of exenatide on incident macroalbuminuria [11].”
Tirzepatide: A New Generation Therapeutic for Diabetes Type 2
Al‐Horani, R. A., & Chedid, M. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666221004151212 · Cited by 15
Alhomoud, I. S., Wheeler, S. E., & Dixon, D. L. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0038 · Cited by 14
Cases, A. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.09.003 · Cited by 16
Bellos, I., Marinaki, S., Λάγιου, Π., & Benetou, V. (2024) · Biomolecules · doi:10.3390/biom15010039 · Cited by 12
Vekić, J., Zeljković, A., Maggio, V., Rizzo, M., & Medenica, S. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01828-2 · Cited by 10
“The EXSCEL trial with exenatide showed similar glycemic and weight benefits, accompanied by trends toward better microvascular outcomes [30].”
Novel pharmacological interventions for diabetic kidney disease
Tan, S. K., Pinzón-Cortés, J. A., & Cooper, M. E. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000935 · Cited by 10
Cox, E. J., Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2020) · US Endocrinology · doi:10.17925/use.2020.16.2.80 · Cited by 10
“73m(2) in the placebo group) was similar in both treatment arms.(15,24) New-onset macroalbuminuria was noted in 2.”
BackgroundResultSantos, G. L., dos Santos, C. F., Rocha, G. R., Calmon, M. S., Lemos, F. F. B., Silva, L. G., Luz, M. S., Pinheiro, S. L. R., Botelho, A. C., & de Melo, F. F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i6.104706 · Cited by 11
“To date, a total of three exenatide-4 based GLP-1 RAs have been evaluated in major trials for their cardiorenal benefits: lixisenatide in the ELIXA trial[149], exenatide by the EXSCEL study[150], and more recently, efpeglenatide in the AMPLITUDE-O trial[151].”
Chalmoukou, K., Polyzos, D., Manta, E., Tatakis, F., Konstantinidis, D., Thomopoulos, C., & Costas, T. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.12.018 · Cited by 10
Recent advances in the pharmacotherapeutic management of diabetic kidney disease
Block, T. J., Batu, D., & Cooper, M. E. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2054699 · Cited by 10
“[44] did not specifically examine renal effects of exenatide but a post-hoc analysis showed a benefit of exenatide on a renal composite including macroalbuminuria and decline in estimated GFR [52].”
BackgroundZhao, X., Lan, J., Yu, X., Zhou, J., Tan, Y. T., Sheng, Z., Li, J., Wang, Y., Chen, R., Liu, C., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.653467 · Cited by 9
Pharmacokinetic and pharmacodynamic studies of supaglutide in rats and monkeys
Liao, Y., Ma, A., Wang, Z., Zhou, Y., Liu, L., Zhang, N., Zhang, L., Prud’homme, G. J., & Wang, Q. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106218 · Cited by 9
Salama, L., & Sinn, L. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf053 · Cited by 9
Morales, E., Martin, W. P., Bevc, S., Jenssen, T. G., Miglinas, M., & Trillini, M. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf069 · Cited by 8
GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2030034 · Cited by 7
Pagidipati, N. J., & DEEDWANIA, P. C. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.04.024 · Cited by 7
Incretins in the Therapy of Diabetic Kidney Disease
Przezak, A., Bielka, W., & Pawlik, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212312 · Cited by 7
“The analysis of prespecified secondary kidney outcomes reported no differences between exenatide and placebo groups [62].”
Zhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1623050/v1 · Cited by 7
Bramlage, P., Vijayan, A., Varghese, T. P., Sadanandan, D. M., Lanzinger, S., & Rodriguez, C. F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70010 · Cited by 7
Alwafi, H. H., Alharbi, S. S., Al-adwani, G. A., Alsanosi, S., Oyelade, T., Almalki, F., Thalib, H. I., Naser, A. Y., Alfahmi, M. Z., Alotaibi, B. J., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1639704 · Cited by 10
Renal hemodynamic changes in patients with type 2 diabetes and their clinical impact
Saulnier, P., & Bjornstad, P. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104175 · Cited by 7
Sreenivasan, C., Parikh, A., Francis, A. J., Kanthajan, T., Pandey, M., AlQassab, O., & Nath, T. S. (2024) · Cureus · doi:10.7759/cureus.66697 · Cited by 5
“Data from large-scale cardiovascular outcome trials (CVOTs) have shown a significant and persistent decrease in atherothrombotic events, particularly among patients with preexisting atherosclerotic cardiovascular disease [7-12].”
BackgroundAlsheikh, A., Al-Jedai, A. H., Almudaiheem, H., Alaidarous, S. B., Alshehri, A., Elbadawi, H., Alghamdi, S., Aljehani, F., Alobaidi, S. A., Altuwaijri, T. A., et al. (2025) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2025.161004 · Cited by 6
Tommerdahl, K. L., Kula, A. J., & Bjornstad, P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2203319 · Cited by 6
“Preliminary results are promising; however, studies are largely limited to soft kidney function outcomes including changes in estimated GFR (eGFR) or urinary albumin-to-creatinine ratio [62–64], new onset macroalbuminuria [65,66], time to new onset macroalbuminuria [67], or persistent macroalbuminuria [68] in lieu of…”
BackgroundAsemi, Z., Salami, R., Salami, M., Mafi, A., Aarabi, M. H., & Vakili, O. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220829102020 · Cited by 7
Vujosevic, S., Toma, C., Ferrulli, A., Cillà, S. D., Nucci, P., & Luzi, L. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02552-w · Cited by 6
“[67], and a post hoc analysis of the trial showed no difference in DR incidence between weekly exenatide and placebo [71].”
Comprehensive management of chronic kidney disease in the old population
Franco, M. E. P., Puente-García, A., Perez-Belmonte, L. M., Pérez, N., Ellingson, S., & Tornero, F. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2551217 · Cited by 5
“This benefit was independent of age (Table 3) 80 .”
Al-Qurain, A. A., Salem, M., Algarzai, B. A., Eljadi, E. M., Elsayed, H., Almuhanna, A., Albuhayji, D. S., Salami, M., Alzahrani, J. A., Alsayyali, J., et al. (2026) · Cureus · doi:10.7759/cureus.100927 · Cited by 7
Management of Diabetes in Patients with Chronic Kidney Disease
Ambalavanan, J., & Caramori, M. L. (2025) · Endocrine Research · doi:10.1080/07435800.2025.2473896 · Cited by 5
Evaluation and Management of Obesity in Chronic Kidney Disease
Friedman, A. N. (2025) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2025.07.004 · Cited by 4
Block, T. J., & Cooper, M. E. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104178 · Cited by 4
Heterogeneity in renal end points of cardiovascular outcomes trials in Type 2 diabetes
Balijepalli, C., Yan, K., Zoratti, M. J., Franklin, M., & Druyts, E. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0137 · Cited by 3
Wang, Y., Feng, L., Wang, Y., Li, B., Liang, N., Song, X., Qin, J., Zhang, M., & Li, Y. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2620155 · Cited by 2
Obesity in Cardiorenal syndrome: Management Opportunities and Challenges
Reaves, A. C., Jaffe, E., & McCallum, W. I. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01352-5 · Cited by 1
Documento de posicionamiento de SEMERGEN sobre la enfermedad renal crónica
Pérez-León, N., García, J. P., Alonso-Álvarez, M. P., & Martínez-Berganza-Asensio, L. (2026) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2026.102690 · Cited by 1
Molecular mechanisms and novel therapeutic targets of diabetic kidney disease
Xu, Z., Yuan, Q., & Zhang, C. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004025 · Cited by 2
Inflammatory Mechanisms in Diabetic Kidney Disease
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_32 · Cited by 1
Katerenchuk, V. I. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.17.8.2021.246795 · Cited by 1
Glucagon-like Peptide-1 Receptor Agonists (GLP1-RA)
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_26 · Cited by 2
Zhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1623050/v2 · Cited by 1
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?
Tan, S. K., & Cooper, M. E. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2277762 · Cited by 1
“Two exendin-based GLP-1RAs, namely lixisenatide and exenatide, did not demonstrate cardio-vascular benefits in the ELIXA [60,61] and EXSCEL [62,63] trials, respectively, although there was a difference in the recruitment and adherence from other GLP-1RA trials, which may have reduced the…”
BackgroundBrief Review of Newer Antiglycemic Agents as Options in the Treatment of Diabetic Kidney Disease
Irons, B. K., Minze, M. G., Lisa, C., & McMurry Michael, E. (2020) · Global Journal of Obesity Diabetes and Metabolic Syndrome · doi:10.17352/2455-8583.000041
“[18-21] However, upon closer evaluation, it appears that the driving force behind the reduction in the composite outcome was change in albuminuria and no study showed an ability to slow the progression of eGFR decline or need for renal replacement therapy.”
Backgroundder Beek, A. B. V. D. A. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.637600695
Wang, W., Lu, J., Li, J., Ma, Y., Wang, X., Zhang, F., Li, C., Jiang, J., & Hao, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-3834867/v1
Wang, W., Lu, J., Li, J., Ma, Y., Wang, X., Zhang, F., Li, C., Jiang, J., & Hao, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-4098611/v1
Metadata
- Authors
- Bethel, M. A., Mentz, R. J., Merrill, P., Buse, J. B., Chan, J. C., Goodman, S. G., Iqbal, N., Jakuboniene, N., Katona, B., Lokhnygina, Y., Lopes, R. D., Maggioni, A. P., Ohman, P., Tankova, T., Bakris, G. L., Hernandez, A. F., & Holman, R. R.
- Affiliations
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- Duke University (US)
- University of North Carolina at Chapel Hill (US)
- Chinese University of Hong Kong (HK)
- St. Michael's Hospital (CA)
- AstraZeneca (United States) (US)
- Department of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC
- Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
- AstraZeneca Research and Development, Gaithersburg, MD
- Medical University of Sofia (BG)
- University of Chicago (US)
- Corresponding author
- Holman, Rury R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-11-22
- Volume
- 43
- Issue
- 2
- Pages
- 446-452
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7411285
- OpenAlex
- W2989595227
- Cited by
- 112
- References
- 32
- Citations by year
- 2026: 7 · 2025: 22 · 2024: 9 · 2023: 22 · 2022: 22 · 2021: 13 · 2020: 17
- FWCI
- 10.55
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Diabetes Care (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Lithuanian University of Health Sciences (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0515-10096)
- National Institutes of Health (UL1TR002489)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- exenatide, GLP-1 receptor agonists, renal function, estimated glomerular filtration rate, macroalbuminuria, diabetic retinopathy, major adverse cardiovascular events, cardiovascular risk reduction, renal function decline, stroke, renal replacement therapy, renal death, type 2 diabetes, EXSCEL trial, subgroup analysis, drug safety in renal impairment, all-cause mortality
- MeSH terms
- Exenatide, Aged, Cardiovascular Diseases, Cardiovascular System, Cause of Death, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Glomerular Filtration Rate, Humans, Kidney, Male, Middle Aged, Risk Factors, Survival Analysis, Treatment Outcome, Microvessels
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.